Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2461 to 2475 of 8904 results

  1. Subcutaneous olanzapine for treating schizophrenia [TSID12289]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  2. Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more responsive mutations in the CFTR gene in people 2 to 5 years [TSID12296]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. Levodopa inhaled for patients with Parkinson's disease who experience 'off' episodes (motor response fluctuations) [TSID8778]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Botulinum injection of abdominal wall prior to massive incisional hernia repair

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  5. Menotrophin prefilled pen for treating anovulation or during controlled ovarian hyperstimulation [TSID12290]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. SEEG-guided radiofrequency thermocoagulation in refractory epilepsy

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  7. Pozelimab with cemdisiran for treating symptomatic generalised myasthenia gravis [TSID12287]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. Transverse Tibial Transport

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  9. Fianlimab with cemiplimab for untreated unresectable advanced melanoma or adjuvant treatment of completely resected high-risk melanoma [TSID12303]

    Awaiting development Reference number: GID-TA11929 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Belzutifan for treating advanced pheochromocytoma or paraganglioma [TSID12304]

    Awaiting development Reference number: GID-TA11928 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. DB-OTO for Hearing loss [TSID12321]

    Awaiting development Reference number: GID-TA11911 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Iptacopan for treating complement 3 glomerulopathy in people 12 to 18 years [TSID12315]

    Awaiting development Reference number: GID-TA11913 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Luspatercept for Anaemia due to myelodysplastic syndromes [TSID12310]

    Awaiting development Reference number: GID-TA11914 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Ravulizumab for treating primary IgA nephropathy [TSID12313]

    Awaiting development Reference number: GID-TA11919 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Setrusumab for treating osteogenesis imperfecta [TSID12308]

    Awaiting development Reference number: GID-TA11921 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development